Deargen, a company specializing in AI new drug development, and Uptera, a new drug development company (TPD), announced on the 16th that they selected two target proteins, including anti-cancer drugs, and signed a joint research contract.
Read More
Technical & News Articles about Deargen
Deargen, a company specializing in AI new drug development, and Uptera, a new drug development company (TPD), announced on the 16th that they selected two target proteins, including anti-cancer drugs, and signed a joint research contract.
Read MoreHANDOK Inc. and Deargen announced that the companies have entered into a strategic collaboration to discover and develop therapies for Oncology and other diseases.
Read More아이엔테라퓨틱스(대표 박종덕)는 디어젠(대표 강길수)의 AI플랫폼을 활용해 난청치료제 신약물질 발굴에 돌입했다고 17일 밝혔다. 아이엔테라퓨틱스는 대웅제약에서 분사된 신약개발 전문 자회사다.
Read Morewe announce our partnership with SK Chemical to co-develop AI-based new drugs. As part of this partnership, SKChemical and Deargen will conduct joint researches on “drug repositioning” and “de novo drug design.”
Read More인공지능(AI) 기반 신약개발 전문기업인 디어젠(Deargen)이 pre-시리즈A로 30억원 규모의 투자유치를 마쳤다고 26일 밝혔다.
Read More알츠하이머병 치료제 신약개발 기업인 아밀로이드솔루션(Amyloid Solution)이 인공지능(AI) 기반 신약개발 전문기업인 디어젠(Deargen)을 인수했다.
Read More2020년 10월 7일 디어젠 주식회사의 이사회를 통해 다음과 같이 신주발행을 결의하였음을 공고합니다.
Read MoreOptipharm and Deargen, Introduced AI to find antigens (epitopes) that cause immune responses to liver cancer cells.
Read MoreDEARGEN participated in KOREA PHARM & BIO 2020 fair in KOREA and received a lot of interest. Especially for the case of COVID-19 treatment prediction using AI.
Read MoreDeep learning models predict old and new drugs that might successfully treat COVID-19.
Read More